Stroke Disorder and Treatment Market Size & Outlook, 2025-2033

Stroke Disorder and Treatment Market Size

The global stroke disorder and treatment market size was valued at USD 22.07 Billion in 2024 and is projected to grow from USD 23.77 Billion in 2025 to reach USD 43.06 Billion by 2033, exhibiting a CAGR of 7.71% during the forecast period (2025–2033). The global stroke disorder and treatment market is largely boosted by the surging incidence of strokes globally, especially in lower and lower-middle-income nations. In light of these surging stroke incidences, several organizations across the world are initiating awareness campaigns to tackle the stroke disorder. Moreover, there has been growing research for developing novel treatments for stroke, which is expected to create opportunities for market expansion.

A stroke, also called a "brain attack," occurs when a blood artery in the brain bursts or is blocked, cutting off blood flow to part of the brain. In either scenario, cerebral tissue is either damaged or destroyed. Permanent brain damage, long-term disability, or even mortality may result from a stroke. A stroke constitutes an urgent medical condition. Mild weakness may progress to paralysis or numbness affecting a single side of the body or face during stroke.

High blood pressure is one of the primary clinical risk factors associated with stroke. Tobacco use, physical inactivity, alcohol consumption, an unhealthy diet, atrial fibrillation, elevated blood lipid levels, genetic predisposition, obesity, stress, and depression are additional risk factors. The long-term impact of a stroke may include physical impairment, impaired communication, unemployment, reduced income, and severed social connections. Accelerated treatment access enhances recovery and saves lives.

To get more insights about this report Download Free Sample Report

Stroke Disorder and Treatment Market Driving Factors

Surging Incidences of Stroke

The prevalence of stroke is surging worldwide. Stroke is the second leading cause of death and the primary cause of disability on a global scale. According to the Global Stroke Factsheet published in 2022 by the World Stroke Organisation (WSO), the lifetime risk of developing a stroke has increased by fifty percent over the past seventeen years, and it is now estimated that one in every four people will experience a stroke in their lifetime.

Stroke incidence surged by 70% between 1990 and 2019, stroke mortality increased by 43%, stroke prevalence increased by 102%, and disability-adjusted life years increased by 143%. The fact that the majority of the worldwide stroke burden (89% of DALYs and 86% of fatalities due to stroke) occurs in lower and lower-middle-income countries is the most striking aspect. This disproportionate burden borne by lower and lower-middle-income co has presented families with fewer resources with an unprecedented challenge. Therefore, the growing prevalence of stroke is boosting the global stroke disorder and treatment market.

Rising Awareness Campaigns

Increasing incidences of stroke and subsequently rising mortality due to stroke have given rise to several awareness campaigns regarding stroke established by the government and non-government organizations. For instance, World Stroke Day, observed on October 29, was officially designated by the World Stroke Congress in 2004 in Vancouver, Canada. Dr. Vladimir Hachinski oversaw the formation of a working group that produced the World Stroke Proclamation in October 2006.

The campaign brings attention to the gravity and prevalence of stroke, enhances knowledge regarding its prevention and treatment, and facilitates improved provisions of support and care for survivors. Organizations throughout the world have arranged events that emphasize testing, education, and attempts to lessen the negative effects of stroke globally. Presently, the WSO maintains a year-round campaign as an interface for policy, advocacy, and outreach to sustain and further advancements achieved on World Stroke Day. Therefore, the aspects above are expected to stimulate market expansion over the forecast period.

Market Restraining Factors

High Cost of Stroke

Stroke ranks among the most prevalent etiologies of neurological impairment and disability among patients. Consequently, it is widely acknowledged that it imposes a significant economic burden, potentially impeding industry statistics. According to WSO estimations, the annual worldwide healthcare expenditure is USD 721 billion (0.66% of the global GDP). In the interim, the increasing prevalence of mechanical thrombectomy, as opposed to medical therapy, which requires a costly angiography suite, imaging studies, and medical devices, may impede market growth.

Market Opportunity

Increasing Research and Development

In recent years, there has been a surge in R&D to develop novel treatments for stroke.

• For instance, in December 2022, Hiroshima University (HU) initiated the human trial for a potentially reversible treatment utilizing therapeutically superior mesenchymal stem cells (MSCs) derived from the cranial bone that offers promise for the treatment of paralysis and language disorder following moderate to severe stroke. In August 2022, the trial's initial intravenous dose of MSCs was administered to the first patient.

Similarly, in September 2023, by employing an innovative approach to preclinical animal research, scientists at the Stroke Preclinical Assessment Network (SPAN) of the National Institutes of Health have identified uric acid as a prospective therapeutic intervention that may facilitate the recovery process following acute ischemic stroke. The study comprehensively evaluated six innovative therapies designed to reduce ischemic brain injury in rodents. The researchers employed rigorous testing procedures typically reserved for human clinical trials. Such research and developments are expected to create opportunities for market growth.

Regional Insights

North America is the most significant global stroke disorder and treatment market shareholder over the forecast period. The regional market dominance can be ascribed to the flourishing prevalence of stroke disease.

• For instance, according to CDC, Stroke accounted for one in every six fatalities caused by cardiovascular disease in 2021. In the United States, stroke incidence occurs at a rate of one occurrence every 40 seconds for an individual. Every 3 minutes and 14 seconds, two persons succumb to the fatal consequences of a stroke. Likewise, it is worth noting that a staggering number of 795,000 persons experience strokes yearly in the United States. Such a high prevalence of stroke is driving the global stroke disorder and treatment market.

Furthermore, stroke is predominantly caused by hypertension, obesity, diabetes, tobacco use, and elevated cholesterol levels. At least one of the following conditions or habits affects one in every three adults in the United States. This is expected to expedite the regional market growth. In addition, there has been a surge in R&D for stroke and stroke-associated treatment.

• For instance, in October 2023, the National Institutes of Health awarded Associate Professor Hui-Ting Goh, Ph.D., and Professor Emeritus Elaine Jackson of the School of Physical Therapy at the Dallas Center a USD 372,870 three-year grant to support their research project titled "Behavioral and Neural Correlates of Post-Stroke Fatigue." All these factors together contribute to market growth in North America.

Asia-Pacific Stroke Disorder and Treatment Market Trends

The Asia-Pacific region is growing significantly owing to the huge target population base, advancements in healthcare infrastructure, soaring disposable income, and growing R&D in stroke management. Various awareness campaigns are conducted in the region to lessen the burden of stroke in Asia-Pacific.

• For instance, the World Health Organization (WHO) South-East Asia Region, in collaboration with Christian Medical College (CMC), Ludhiana, Punjab, India, has initiated a program known as the "Technical Support for Mentoring of Stroke Care Improvement Program." This initiative spans across six countries in the South-East Asia region. With the assistance of the WHO Sri Lanka office and the Non-communicable Diseases unit of the Ministry of Health, Sri Lanka is also participating in the aforementioned program in collaboration with the National Stroke Association. A stroke care delivery evaluation in Sri Lanka was conducted from May to December 2022 as an initial step of the project. Such programs are expected to boost the market growth.

The European region is mainly boosted by the elevated per capita income, favorable reimbursement policies, flourishing geriatric population, and increased health awareness. In addition, the favorable government initiatives in this region support stroke awareness in driving market growth.

• For instance, in May 2021, health ministries throughout Europe were urged to sign the Declaration for Action on the Stroke Action Plan for Europe to combat one of the primary causes of disability and death. This initiative, spearheaded by the Stroke Alliance for Europe (SAFE) and The European Stroke Organisation (ESO), seeks to persuade European nations to sign the Stroke Action Plan for Europe Declaration and lend their support to the fight against stroke throughout Europe as a symbol of their dedication to enhancing prevention, treatment, care, and assistance.

Type Insights

The ischemic stroke segment is the largest revenue contributor to the market and is expected to expand over the forecast period. An ischemic stroke is a cerebrovascular event characterized by the obstruction or reduction of blood flow to a specific region of the brain, commonly caused by a blood clot or the development of atherosclerosis, which involves the accumulation of lipid deposits inside the arterial walls. The obstruction hinders the supply of oxygen and nutrients to the cerebral cells, resulting in impairment and, potentially, the demise of cerebral tissue in the impacted region. Ischemic strokes are the most prevalent form of stroke, constituting roughly 87% of the total number of strokes. This drives the segment growth in the market.

Medicine Insights

The anticoagulants segment dominates the global market and is expected to expand substantially over the forecast period. Anticoagulants, which are frequently prescribed to reduce the risk of stroke in specific individuals, are a class of blood-thinning drugs. The key players in the market are consistently striving to introduce new anticoagulants for treating stroke, driving the market growth.

• For instance, in February 2023, Bayer, a German pharmaceutical company, was granted expedited status by the U.S. Food and Drug Administration (FDA) for its novel blood thinner, asundexian. This medication is specifically developed to mitigate the occurrence of specific stroke types. Bayer's pursuit of this regulatory milestone aligns with its objective to build upon the achievements of its anticoagulant drug, Xarelto.

Treatment Insights

The tissue plasminogen activator (tPA) segment owns the highest market share and is expected to grow substantially during the forecast period. Tissue Plasminogen Activator (tPA) is an enzyme intrinsic to the human body and essential for fibrinolysis, the process by which blood clots dissolve. tPA is generated and secreted by specific cells within the body and endothelial cells that line blood vessels. Therapeutically, tPA is predominantly employed to treat specific medical conditions, including acute myocardial infarctions and ischemic strokes. During such circumstances, tPA may be utilized as a pharmaceutical agent to facilitate the dissolution of blood clots, impeding the supply of vital organs such as the brain or heart. This could reduce tissue injury and preserve lives.

List of key players in Stroke Disorder and Treatment Market

1. AbbVie
2. Medtronic
3. Pfizer
4. Bristol Myers Squibb
5. F. Hoffmann-La Roche
6. Amgen Inc
7. Biogen Inc
8. Boston Scientific Corporation
9. AstraZeneca
10. Royal Philips
11. Johnson & Johnson Services
12. GE Healthcare

To get more findings about this report Download Market Share

Recent Developments

• October 2023- Argenica, a biotechnology company headquartered in Australia, received approval to initiate Phase II clinical trials involving ARG-007, a therapeutic intervention designed to assist patients with acute ischaemic stroke (AIS).
• October 2023- A global leader in health technology, Royal Philips, and the World Stroke Organization (WSO), the only global non-governmental organization dedicated to stroke, signed a two-year partnership today to expand access to high-quality stroke care.